Every value below carries the sentence it was read from.
125 sources stand behind the page.
Field
Value
Cited text
Known as
Ixabepilone
“Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine,...” NCT01156753 ↗112
“One of the following Treatment of Physician Choice will be administered per standard of care:
eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel” NCT01492101 ↗
“A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma.” PMID 20179242 ↗Feb 2010
“physician choice: taxane-based chemotherapy to include Paclitaxel, Docetaxel, Abraxane or Ixabepilone given as standard of care” NCT02067416 ↗
“Ixabepilone is a semisynthetic analog of the natural product epothilone B” NCT01454479 ↗
ChEMBL registry synonym — accepted as the source's own labelCHEMBL1201752 ↗
Known as
BMS 247550
“The purpose of this study is to test how BMS-247550 (ixabepilone) affects the removal of capecitabine from the body and how capecitabine affects the removal of BMS-247550 from the body.” NCT00207129 ↗12
“Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients With Refractory Solid Tumors and Leukemias” NCT00030108 ↗
“Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.” PMID 16314632 ↗Dec 2005
“A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study.” PMID 16699973 ↗Nov 2006
“Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.” PMID 17261851 ↗Jan 2007
“Ixabepilone [BMS-247550] will be administered on Day 1 (D1) every three weeks as a 3-hour infusion at a dose of 40 mg/m2.” NCT00790894 ↗
“A Multicenter Phase II Study Of BMS 247550 (Epothilone B Analogue) In Indolent Lymphoproliferative Disorders” NCT00052572 ↗
ChEMBL registry synonym — accepted as the source's own labelCHEMBL1201752 ↗
Known as
Ixabepilona
ChEMBL registry synonym — accepted as the source's own labelCHEMBL1201752 ↗
Known as
Ixempra
“A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma.” PMID 20179242 ↗Feb 20102
“A Phase II Clinical Trial of Ixabepilone (Ixempra [R], BMS-247550, NSC 710428), an Epothilone B Analog, in Cervical Cancer” NCT00924066 ↗
“A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra)” NCT01454479 ↗
ChEMBL registry synonym — accepted as the source's own labelCHEMBL1201752 ↗
Known as
NSC 710428
“A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology...” PMID 25091619 ↗Aug 20144
“Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients With Refractory Solid Tumors and Leukemias” NCT00030108 ↗
“A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study.” PMID 16699973 ↗Nov 2006
“A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma.” PMID 20179242 ↗Feb 2010
“A Phase II Clinical Trial of Ixabepilone (Ixempra [R], BMS-247550, NSC 710428), an Epothilone B Analog, in Cervical Cancer” NCT00924066 ↗
Known as
NSC 710428D
“A Phase II Study Of Epothilone B Analog BMS-247550 (NSC 710428D) In Patients With Advanced Colorectal Carcinoma” NCT00022477 ↗1
“Epothilone B Analogue BMS-247550 (NSC 710428D)” NCT00049400 ↗
Known as
NSC-747973
ChEMBL registry synonym — accepted as the source's own labelCHEMBL1201752 ↗
Action
Inhibit
“Ixabepilone is a tubulin-inhibiting agent with low susceptibility to multiple resistance mechanisms including β3T isoform expression in several tumor models.” PMID 23589560 ↗Apr 2013
Modality
Small molecule
“novel epothilone analog ixabepilone” PMID 17261851 ↗Jan 2007
Route
Intravenous
“Part I: Patients with advanced solid tumors receive BMS-247550 IV over 1 hour every 3 weeks.” NCT00005807 ↗